Form 10-Q America Great Health For: Mar 31

May 25, 2022 1:01 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
amgreat20220331_10q.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                        to                     

 

Commission File No. 000-27873

 

America Great Health

(Exact name of registrant as specified in its charter)

 

Wyoming

(State or other jurisdiction of incorporation or organization)

98-0178621

(I.R.S. Employer Identification No.)

 

 

1609 W Valley Blvd Unit 338A

Alhambra, CA

(Address of principal executive offices)

91803

(Zip Code)

 

(888) 988-1333

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

 

Accelerated filer ☐

 

 

 

Non-accelerated filer

 

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant’s common stock as of March 31, 2022 was 21,089,355,704.

 

 

 

 

AMERICA GREAT HEALTH AND SUBSIDIARIES

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION

3

 

 

 

ITEM 1

Condensed Consolidated Financial Statements (Unaudited)

3

 

 

 

ITEM 2

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

 

 

 

ITEM 3

Quantitative and Qualitative Disclosures About Market Risk

24

 

 

 

ITEM 4

Controls and Procedures

24

 

 

 

 

 

 

PART II – OTHER INFORMATION

25

 

 

 

ITEM 1

Legal Proceedings

25

 

 

 

ITEM 1A

Risk Factors

25

 

 

 

ITEM 2

Unregistered Sales of Equity Securities and Use of Proceeds

25

 

 

 

ITEM 3

Defaults Upon Senior Securities

25

 

 

 

ITEM 4

Mine Safety Disclosures

25

 

 

 

ITEM 5

Other Information

25

 

 

 

ITEM 6

Exhibits

25

 

 

 

PART I FINANCIAL INFORMATION

 

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider” or similar expressions are used.

 

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

 

Item 1. Financial Statements

 

America Great Health and Subsidiaries

Condensed Consolidated Balance Sheets

 

   

March 31,

   

June 30,

 
   

2022

   

2021

 

ASSETS

 

(Unaudited)

         
                 

CURRENT ASSETS

               

Cash

  $ 106,304     $ 396,136  

Inventory

    148,595       7,848  

Other receivable

    80,649       61,136  

Supplier advances

    10,250       17,600  

TOTAL CURRENT ASSETS

    345,798       482,720  
                 

Right-of-use asset

    89,161       126,927  

Other asset – Deposits

    2,700       700  

Property and equipment, net

    29,523       12,671  
                 

TOTAL ASSETS

  $ 467,182     $ 623,018  
                 

LIABILITIES AND SHAREHOLDERS' DEFICIT

               

CURRENT LIABILITIES

               

Accounts payable and accrued expense

  $ 1,581,030     $ 57,209  

Income tax payable

    -       800  

Due to related party

    523,935       323,750  

Unearned income

    44,900       -  

Short term loan

    160,000       -  

Lease liability - current

    52,601       50,672  

TOTAL CURRENT LIABILITIES

    2,362,466       432,431  
                 

Lease liability - non current

    36,560       76,255  

Accrued interest

    138,289       12,159  

Long term loan

    1,032,138       570,000  
                 

TOTAL LIABILITIES

    3,569,453       1,090,845  
                 

SHAREHOLDERS' DEFICIT

               

 

               

Redeemable, convertible preferred stock, 10,000,000 shares authorized;

Series A voting preferred stock, zero shares issued and outstanding

    -       -  

Common stock, no par value, unlimited shares authorized;

21,089,355,704 and 21,070,866,399 shares issued and outstanding

    -       -  

Additional paid-in capital

    3,195,286       3,087,869  

Accumulated deficit

    (6,297,557 )     (3,555,696 )
                 

TOTAL AMERICA GREAT HEALTH SHAREHOLDERS' EQUITY(DEFICIT)

    (3,102,271 )     (467,827 )

Non-controlling interest

    -       -  

TOTAL SHAREHOLDERS' EQUITY(DEFICIT)

    (3,102,271 )     (467,827 )
                 

TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT

  $ 467,182     $ 623,018  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

America Great Health and Subsidiaries

Condensed Consolidated Statements of Operations

 

    Three Months Ended March 31,    

Nine Months Ended December 31,

 
   

2022

   

2021

   

2022

   

2021

 
   

(Unaudited)

   

(Unaudited)

 
                                 

Sales

  $ 2,744     $ 195,535     $ 158,424     $ 195,671  
                                 

Cost of goods sold

    360       143,905       1,551,367       144,049  
                                 

Gross profit

    2,384       51,630       (1,392,943 )     51,622  
                                 

Selling, general and administrative expenses

                               

Professional fee

    121,948       50,185       374,548       69,810  

Payroll expense

    312,637       -       549,964       -  

Office expense & supplies

    28,339       -       69,318       -  

Rent expense

    22,309       -       60,048       -  

Advertising and promotion

    24,079       -       60,064       -  

Other

    140,330       48,504       191,879       64,688  
      649,642       98,689       1,305,821       134,498  
                                 

Loss from operations

    (647,258 )     (47,059 )     (2,698,764 )     (82,876 )
                                 

Other income (expenses)

                               

Loss on equity investment

    -       -       -       -  

Interest expense

    (55,283 )     (2,156 )     (136,142 )     (5,275 )

Other income

    93,010       -       93,045       -  
      37,727       (2,156 )     (43,097 )     (5,275 )
                                 

Loss before income taxes

    (609,531 )     (49,215 )     (2,741,861 )     (88,151 )
                                 

Income tax provision

    -       -       -       -  
                                 

Loss from continuing operations

    (609,531 )     (49,215 )     (2,741,861 )     (88,151 )
                                 

NET LOSS

  $ (609,531 )   $ (49,215 )   $ (2,741,861 )   $ (88,151 )
                                 
                                 

Net loss attributable to non-controlling interest

    -       -       -       -  
                                 

NET LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH

  $ (609,531 )   $ (49,215 )   $ (2,741,861 )   $ (88,151 )
                                 
                                 

BASIC AND DILUTED LOSS PER SHARE

  $ (0.00 )   $ (0.00 )   $ (0.00 )   $ (0.00 )

 

                               

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING

BASIC AND DILUTED

    21,089,355,704       20,292,390,328       21,073,497,199       20,254,537,034  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

America Great Health and Subsidiaries

Consolidated Statement of Shareholders' Deficit

 

                                   

Total

 
    Common Stock    

Additional

   

Accumulated

   

Shareholder’s

 
   

Shares

   

Amount

   

Paid-in Capital

   

Deficit

   

Equity

 
                                         

Balance, June 30, 2020

    20,236,021,836     $ -     $ 3,071,635     $ (3,286,642 )   $ (215,007 )
                                         

Imputed interest

    -       -       1,489       -       1,489  

Net loss

    -       -       -       (2,671 )     (2,671 )
                                         

Balance, September 30, 2020(Unaudited)

    20,236,021,836     $ -     $ 3,073,124     $ (3,289,314 )   $ (216,190 )
                                         

Imputed interest

    -       -       1,629       -       1,629  

Net loss

    -       -       -       (36,268 )     (36,268 )
                                         

Balance, December 31, 2020(Unaudited)

    20,236,021,836     $ -     $ 3,074,753     $ (3,325,582 )   $ (250,829 )
                                         

Issuance of common stock for compensation

    127,582,658       -       1,276       -       1,276  

Imputed interest

    -       -       2,157       -       2,157  

Net loss

    -       -       -       (49,215 )     (49,215 )
                                         

Balance, March 31, 2021 (Unaudited)

    20,363,604,494     $ -     $ 3,078,186     $ (3,374,797 )   $ (296,611 )
                                         

Issuance of common stock for compensation

    78,811,905               788               788  

Issuance of common stock for debt

    13,450,000               135               135  

Issuance of common stock for equity trust

    70,000,000               700               700  

Issuance of common stock for merger & acquisition

    545,000,000               5,450               5,450  

Imputed interest

                    2,610               2,610  

Net loss

                            (180,900 )     (180,900 )

Balance, June 30, 2021

    21,070,866,399     $ -     $ 3,087,869     $ (3,555,696 )   $ (467,827 )
                                         

Imputed interest

    -       -       2,814       -       2,814  

Net loss

    -       -       -       (331,272 )     (331,272 )
                                         

Balance, September 30, 2021 (Unaudited)

    21,070,866,399     $ -     $ 3,090,683     $ (3,886,968 )   $ (796,285 )
                                         

Issuance of common stock for debt

    5,021,840       -       -       -       -  

Imputed interest

    -       -       2,723       -       2,723  

Net loss

    -       -       -       (1,801,058 )     (1,801,058 )
                                         

Balance, December 31, 2021 (Unaudited)

    21,075,888,239     $ -     $ 3,093,406     $ (5,688,026 )   $ (2,594,620 )
                                         

Issuance of common stock for debt

    12,167,465       -       -       -       -  

Issuance of common stock

    1,300,000               97,500               97,500  

Imputed interest

    -       -       4,380       -       4,380  

Net loss

                            (609,531

)

    (609,531

)

                                         

Balance, March 31, 2022( Unaudited)

    21,089,355,704     $ -     $ 3,192,550     $ (6,297,557 )   $ (3,102,271 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

America Great Health and Subsidiaries

Condensed Consolidated Statements of Cash Flows

 

   

Nine Months Ended March 31,

 
   

2022

   

2021

 

Cash Flows from Operating Activities

 

(Unaudited)

 
                 
                 

Net loss

  $ (2,741,861 )   $ (88,151 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Stock compensation

    -       1,276  

Imputed interest

    9,921       5,275  

Changes in operating Assets and Liabilities:

               

Other receivable

    (9,163 )     (6,765 )

Inventory

    (140,747 )     (606 )

Accounts payable and accrued expense

    1,518,818       (7,254 )

Unearned revenues

    44,900       -  

Income tax payable

    (800 )     (800 )
                 

Net cash used in operating activities from continuing operations

    (1,318,932 )     (97,025 )

Net cash used in operating activities from discontinued operations

    -       -  
                 

Net cash used in operating activities

    (1,318,932 )     (97,025 )
                 

Cash Flows from Investing Activities

               
                 

Purchase of property and equipment

    (16,852 )     -  
                 

Net cash provided by investing activities

    (16,852 )     -  
                 

Cash Flows from Financing Activities

               
                 

Short term loan

    160,000       -  

Long term loan

    588,268       -  

Issuance of common stock

    97,500       -  

Advances from related party

   
-
      201,660  

Repayment to related party

    200,184       (79,548 )

Net cash provided by financing activities from discontinued operations

    1,045,952       122,112  
                 

Net cash provided by financing activities

    1,045,952       122,112  
                 

Net increase in cash

    (289,832 )     25,087  
                 

Cash beginning of period

    396,136       166  

Cash end of period

  $ 106,304     $ 25,253  
                 
                 

Interest paid

  $ -     $ -  
                 

Taxes paid

  $ -     $ -  
                 

Non-cash transactions

               
                 

Shares issued for equity investment

  $ -     $ -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

AMERICA GREAT HEALTH AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

NOTE 1 BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.

 

Nature of the Business

 

America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

 

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

 

On March 9, 2017, the Company formed a wholly-owned subsidiary, America Great Health, under the laws of the State of California.

 

On June 24, 2019, the Company registered a wholly-owned subsidiary in China, US-China Mega Beauty Health Industry Development Co., Ltd. The subsidiary is mainly engaged in mergers and acquisitions, investments and financings, and marketing of medical equipment and health products in China.

 

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell. On April 6, 2021, the Company issued 510,000,000 shares of common stock to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomous in its day-o-day operations, including recruiting and retaining management team members. Because the Company does not have significant control over Purecell, the acquisition is accounted for as an equity investment. This transaction was completed in May 2021.

 

On December 7, 2020, the Company’s wholly-owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China as “Sijinsai (Hainan) Biological Tech Ltd.” On July 9, 2021, the Company paid its first investment of $50,000. In July 2021, the Company paid Dr. Aihua Guo $100,000 as a professional expense.

 

 

On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready for production.

 

On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated.

 

On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC, under the laws of the State of California.

 

On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement.

 

On November 15, 2021, the Company set up a 100% owned subsidiary Gof Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF.

 

On February 4, 2021, the Company set up a 100% owned subsidiary International Institute of Great Health, Inc. (IIGH) under the laws of the State of California. The Company wholly owned research institute will bring together doctors and professor-level experts from different countries and regions in the world. The research fields involve biomedicine, clinical medicine, health management, information technology, data analysis, software development, artificial intelligence, industrial planning, financial investment, etc.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has incurred recurring net losses. For the nine months ended March 31, 2022, the Company recorded a net loss of $2,739,121, used cash to fund operating activities of $1,318,932, and at March 31, 2022, had a shareholders’ deficit of $3,102,271. These factors create substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

 

Our cash needs for the nine months ended March 31, 2022 were primarily met by loans and advances from current majority shareholder. As of March 31, 2022, we had a cash balance of $106,304. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

 

 

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

 

Basis of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its current wholly owned subsidiary, America Great Health in California. Intercompany transactions and accounts have been eliminated in consolidation.

 

Cash

 

The Company considers all highly liquid debt instruments purchased with maturity periods of six months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance.

 

The Company’s bank account in the United States is protected by FDIC insurance. As of March 31, 2022 and June 30, 2021, the Company’s bank account in the United States had $106,304 and $398,136, respectively, exceeding FDIC insurance of $250,000.

 

Estimates

 

The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock issued for services, debt and equity investment. Actual results could differ from those estimates.

 

Revenues

 

Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

 

 

executed contract(s) with customers that the Company believes is legally enforceable;

 

 

identification of performance obligation in the respective contract;

 

 

determination of the transaction price for each performance obligation in the respective contract;

 

 

allocation of the transaction price to each performance obligation; and

 

 

recognition of revenue only when the Company satisfies each performance obligation.

 

The Company sells health related products through wholesale and retailers. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue.

 

 

Product Revenue

 

A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer.

 

Shipping and handling activities are performed upon delivery to the third-party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented.

 

Inventories

 

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the nine months ended March 31, 2022 and 2021, the Company has not made provision for inventory in regards to slow moving or obsolete items.

 

Equity Method Investments

 

We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the nine months ended March 31, 2022.

 

Fair Value Measurements

 

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

 

Level 3—Unobservable inputs based on the Company’s assumptions.

 

The Company is required to use observable market data if available without undue cost and effort.

 

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

 

Loss per Share

 

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the nine months ended March 31, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect.

 

 

Income Taxes

 

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of March 31, 2022, and June 30, 2021.

 

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

 

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

 

In January 2020, the FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivative and Hedging (Topic 815), which clarifies the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance clarifies how to account for the transition into and out of the equity method of accounting when considering observable transactions under the measurement alternative. The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim reporting periods within those annual periods, with early adoption permitted. The Company have adopted this ASU on the consolidated financial statements in the year ended June 30, 2021. The adoption had no material impact on the consolidated financial statements in the year ended June 30, 2021 and nine months ended March 31, 2022.

 

In August 2020, the FASB issued ASU 2020-06, “DebtDebt with Conversion and Other Options (Subtopic 470-20) and Derivatives and HedgingContracts in Entitys Own Equity (Subtopic 815 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

NOTE 3 OTHER RECEIVABLE

 

As of March 31, 2022 and June 30, 2021, other receivable amounted to $80,649 and $61,136, respectively. Other receivable consists of the following:

 

   

March 31, 2022

   

June 30, 2021

 

Rent deposit

  $ 11,136     $ 11,136  

Loan to a third party

    50,000       50,000  

Employee advance

    13,208       -  

Others

    6,275       -  

Total

  $ 80,649     $ 61,136  

 

Loan to a third party amounted $50,000 and $50,000 as of March 31, 2022 and June 30, 2021. Loan to a third party is due on July 30, 2021, interest free, no collateral, and interest free. The loan has not been paid back as of the reporting date.

 

 

NOTE 4 RELATED PARTY TRANSACTIONS

 

During the nine months ended March 31, 2022, the Company's current majority shareholder advanced $495,124 to the Company as working capital and the Company repaid $295,100 to the shareholder. As of March 31, 2022 and June 30, 2021, the Company owed its current majority shareholder of $273,935 and $323,750 respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted $9,921 and $5,275 for the nine months ended March 31, 2022 and 2021 and was recorded as paid in capital, respectively.

 

NOTE 5 SHORT TERM LOAN

 

As of March 31, 2022, short term loan amounted to $160,000. The loan is due July 10, 2022, interest free, and no collateral. As of March 31, 2022, the Company issued 400,000 of the 640,000 shares of restricted shares of common stock as bonus shares to the lenders, and the balance of 240,000 share of restricted shares were issued in April 12, 2022.

 

NOTE 6 LONG TERM LOAN

 

As of March 31, 2022 and June 30, 2021, long term loan amounted to $1,170,427 and $582,159, respectively. The loan has an annual interest rate of 20%. The principal and interest are due in five years. Interest expense incurred for the nine months ended March 31, 2022 and 2021 amounted to $138,289 and $0, respectively.

 

As of March 31, 2022, long term loan consisted of the following:

                       
   

Principal

   

Interest

   

Balance

 

Received long term loan on April 27, 2021

  $ 200,000     $ 37,041     $ 237,041  

Received long term loan on June 3, 2021

    290,000       47,830       337,830  

Received long term loan on June 4, 2021

    50,000       8,246       58,247  

Received long term loan on June 23, 2021

    30,000       4,619       34,619  

Received long term loan on July 12, 2021

    10,000       1,436       11,436  

Received long term loan on September 1, 2021

    60,000       6,937       66,937  

Received long term loan on September 22, 2021

    50,000       5,205       55,205  

Received long term loan on September 27, 2021

    50,000       5,068       55,068  

Received long term loan on September 30, 2021

    10,000       997       10,997  

Received long term loan on October 29, 2021

    12,138       1,018       13,156  

Received long term loan on November 9, 2021

    50,000       3,890       53,890  

Received long term loan on November 16, 2021

    140,000       10,356       150,356  

Received long term loan on November 18, 2021

    50,000       3,644       53,644  

Received long term loan on November 29, 2021

    20,000       1,337       21,337  

Received long term loan on November 30, 2021

    10,000       663       10,663  

Total

  $ 1,032,138     $ 138,289     $ 1,170,427  

 

On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021.

 

On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021.

 

 

On May 31, 2021, the Company signed a loan agreement of $50,000 with an unrelated party, with 500,000 shares as collateral, and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $20,000 on June 3, 2021. On June 18, 2021, the Company issued 200,000 shares to an unrelated party. The Company received the proceed of $30,000 on June 23, 2021. On October 28, 2021, the Company issued 240,000 shares to an unrelated party, and the remaining 60,000 shares have not been issued.

 

On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.

 

In October 2021, the Company issued 2,620,000 shares to 4 unrelated parties as collateral for loans of $170,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in July and September 2021.

 

On October 28, 2021, the Company issued 100,000 shares to an unrelated party as collateral for a loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021.

 

In November 2021, the Company issued 2,061,840 shares to 4 unrelated parties as collateral for loans of $202,138. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in October and November 2021.

 

In November 2021, the Company signed 3 loan agreements of $80,000 with 3 unrelated parties, with 800,000 shares as collateral , and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $80,000 in November 2021. These shares were issued in February 2022.

 

NOTE 7 CONVERTIBLE, REDEEMABLE PREFERRED STOCK

 

During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

 

 

The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change.

 

In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000.

 

There were no preferred shares outstanding as of March 31, 2022 and June 30, 2021.

 

NOTE 8 SHAREHOLDERS DEFICIT

 

At March 31, 2022 and June 30, 2021, the Company had 21,089,355,704 and 21,070,866,399 shares issued and outstanding, respectively.

 

1) Shares issued for equity investment

 

On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date.

 

Equity Investment in Purecell Group

 

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd (“Purecell”) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share.

 

On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share.

 

On March 30, 2022, the Company issued 1,300,000 shares to an US individual at $0.075 per share.

 

2) Shares issued for stock compensation

 

On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services.

 

The issuance of these shares was recorded at fair market value of $0.00001 per share.48,220,124 shares were issued at fair market value of $482.

 

On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share. 79,362,534 shares were issued at fair market value of $794.

 

 

On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. 50,000,000 shares were issued at fair market value of $500.

 

On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 6,621,905 shares were issued at fair market value of $66.

 

On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 1,300,000 shares were issued at fair market value of $13.

 

On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 7,140,000 shares were issued at fair market value of $71.

 

On May 18 , 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. On May 26, 2021, the Company issued 2,000,000 shares of common stock to Dr. Tsai as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 2,000,000 shares were issued at fair market value of $20.

 

On May 26, 2021, the Company issued an aggregate of 450,000 shares of common stock to 3 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 450,000 shares were issued at fair market value of $5.

 

On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 11,300,000 shares were issued at fair market value of $113.

 

On February 2, 2022, the Company issued an aggregate of 10,967,465 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 11,367,465 shares were issued at fair market value of $109.

 

3) Shares issued for loan as collateral

 

On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021.

 

On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021.

 

On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.

 

 

On May 31, 2021, the Company signed a loan agreement of $50,000 with an unrelated party, with 500,000 shares as collateral ,and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $20,000 on June 3, 2021. On June 18, 2021, the Company issued 200,000 shares to an unrelated party. The Company received the proceed of $30,000 on June 23, 2021. On October 28, 2021, the Company issued 240,000 shares to an unrelated party, and the remaining 60,000 shares have not been issued.

 

In October 2021, the Company issued 2,620,000 shares to 4 unrelated parties as collateral for loans of $170,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in July and September 2021.

 

On October 28, 2021, the Company issued 100,000 shares to an unrelated party as collateral for a loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021.

 

In November 2021, the Company issued 2,061,840 shares to 4 unrelated parties as collateral for loans of $202,138. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in October and November 2021.

 

On February 2, 2022, the Company issued 800,000 shares to 3 unrelated parties as collateral for loan of $80,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $80,000 in November 2021.

 

NOTE 9 EQUITY INVESTMENT

 

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share.

 

On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share.

 

 

The following table summarizes the income statement of Purecell.

 

   

From 07/01/2021 to

 
   

03/31/2022

 
         

Sales

  $ 357,050  

Gross profit

    163,438  

Net loss

    (333,392 )

51% share

    (170,030 )

 

The following table provides the summary of equity investment in Purecell.

 

   

As of March

 
      31, 2022  
         

Beginning balance of investment

    5,450  

Loss on equity investment

    (5,450 )

Ending balance of investment

    -  

 

NOTE 10 INCOME TAXES

 

As of March 31, 2021, the Company had federal and California income tax net operating loss carryforwards of approximately $5.7 million. These net operating losses will begin to expire 20 years from the date the tax returns are filed.

 

Uncertain Tax Positions

 

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the nine months ended March 31, 2022 and 2021, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

 

NOTE 11 LEASE

 

The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements.

 

Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the three months ended March 31, 2022, the Company recognized approximately $13,967 in total lease costs. For the nine months ended March 31, 2022, the Company recognized approximately $41,901 in total lease costs.

 

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments.

 

Information related to the Company’s operating ROU assets and related lease liabilities are as follows:

 

   

Nine months ended

 
   

March 31, 2022

 

Cash paid for operating lease liabilities

  $ 41,901  

Weighted-average remaining lease term

    1.672  

Weighted-average discount rate

    5 %

Minimum future lease payments

  $ 89,161  

 

 

The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending March 31:

 

2022

  $ 12,906  

2023

    53,265  

2024

    22,990  

2025

    -  

2026

    -  

Total minimum payments

    89,161  

Less: short-term lease liability

    (52,601 )
         

Long-term lease liability

  $ 36,560  

 

NOTE 12 SUBSEQUENT EVENTS

 

On April 12, 2022, the Company issued 240,000 balance shares of the total 640,000 shares of restricted shares of common stock as bonus shares to two unrelated lenders who loaned the Company $160,000 on January 11, 27, and February 2, 2022.

 

On January 28, 2022, the Company signed a company stock & payment exchange agreement with a supplier. The Company offers to pay the supplier the $295,000 for product with 15,000,000 shares of common stock. The 15,000,000 shares of common stock are transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of May 22, 2022, the Company hasn’t issue any shares of common stock to the supplier for the purchase of products.

 

On January 28, 2022, the Company signed a company stock & payment exchange agreement with a supplier. The Company offers to pay the supplier the $1,100,000 for product with 35,000,000 shares of common stock. The 35,000,000 shares of common stock are transferred to the supplier, or any third party designated by the supplier within 60 days, and no later than March 30, 2022. However, as of May 22, 2022, the Company hasn’t issue any shares of common stock to the supplier for the purchase of products.

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward Looking Statement Notice

 

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Crown Marketing, (“we”, “us”, “our” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

 

History and Organization

 

America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

 

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

 

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

 

On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.

 

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021.

 

On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s quarterly report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for 40% equity ownership. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China, fully known as Sijinsai (Hainan) Biological Tech Ltd. On July 9, 2021, the Company paid the first investment of $50,000. In July 2021, the Company paid Dr. Aihua Guo $100,000 as prepaid expense.

 

 

On September 3, 2021, America Great Health (the “Company”) entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626, 286 for a purchase price of $7,000,000 (the “Agreement”). The purchase price shall be paid as follows : (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.

 

On September 9, 2021, America Great Health (the “Company”) entered into an Agreement with Wang’s Property Investment & Management LLC (“Wang”) to purchase some real estate properties held by Wang for a purchase price of $7,000,000. The Company and Wang have both agreed that they will not conduct due diligence in order for the transaction to proceed (the “transaction”, the “Agreement”). As of the reporting date, the Company has not made any payment for the transaction and the transaction has not completed.

 

The properties acquired are commercial and residential properties located in Illinois for rental purposes. AAGH was purchased with a cash contribution of $7,000,000 and paid before April 10, 2022. The company will set up a management department or have professionals to manage and operate the property.

 

On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC.

 

On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement.

 

On November 15, 2021, the Company set up a 100% owned subsidiary Gof Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF.

 

Overview of Business

 

Our mission is to invest in innovative technologies intergrated with business development in the healthcare ecosystem.

 

We are focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy and regenerational medicine and supplements manufacturing and sales.

 

On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626, 286.37 for a purchase price of $7,000,000, The purchase price shall be paid as follows : (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. With the asset acquisition from Wang’s Property Investment & Management LLC, the Company will diversify its business into property investment and management.

 

 

Results of Operations

 

Results of Operations for the three and nine months ended March 31, 2022 compared to the three and nine months ended March 31, 2021.

 

Sales amounted $2,744 and $195,535 for the three months ended March 31, 2022 and 2021, respectively. Sales amounted $158,424 and $195,671 for the nine months ended March 31, 2022 and 2021, respectively.

 

Cost of goods sold amounted $360 and $143,905 for the three months ended March 31, 2022 and 2021, respectively. Cost of goods sold amounted $1,551,367 and $144,049 for the nine months ended March 31, 2022 and 2021, respectively.

 

Gross profit amounted $2,384 and $51,630 for the three months ended March 31, 2022 and 2021, respectively. Gross loss amounted $1,392,943 and gross profit was $51,622 for the nine months ended March 31, 2022 and 2021, respectively.

 

Operating expenses incurred for the three months ended March 31, 2022 and 2021 was $649,642 and $98,689, respectively. Operating expenses incurred for the nine months ended March 31, 2022 and 2021 was $1,305,821 and $134,502, respectively.

 

Our net loss for the three months ended March 31, 2022 and 2021 was $606,791 and $49,216, respectively. Our net loss for the nine months ended March 31, 2022 and 2021 was $2,739,121 and $88,151, respectively. The decrease in net loss was mainly due to decrease in professional fees.

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has incurred recurring net losses. For the nine months ended March 31, 2022, the Company recorded a net loss of $2,739,121, used cash to fund operating activities of $1,068,932, cash used for investing activities of $16,852 and cash provided by financing activities of $795,952. For the nine months ended March 31, 2021, the Company recorded a net loss of $88,151, used cash to fund operating activities of $97,025 and cash provided by financing activities of $122,112. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company is raising the additional capital to achieve profitable operations.

 

Our cash needs for the nine months ended March 31, 2022 were primarily met by loans and advances from current majority shareholder. As of March 31, 2022, we had a cash balance of $106,304. Our new majority shareholders will need to provide all of our working capitals going forward.

 

Primarily as a result of our recurring losses and our lack of liquidity, we received a report from our independent registered public accounting firm for our financial statements for the nine months ended March 31, 2022 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern.

 

Financial Position

 

As of March 31, 2022, we had $106,304 in cash, negative working capital of $1,068,929 and an accumulated deficit of $6,294,814.

 

 

Critical Accounting Policies and Estimates

 

Estimates

 

The preparation of these consolidated financial statements (“CFS”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others, the fair value of shares of common stock issued for services. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

 

Revenues

 

Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:

 

 

executed contract(s) with customers that the Company believes is legally enforceable;

 

 

identification of performance obligation in the respective contract;

 

 

determination of the transaction price for each performance obligation in the respective contract;

 

 

allocation of the transaction price to each performance obligation; and

 

 

recognition of revenue only when the Company satisfies each performance obligation.

 

Inventories

 

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances.

 

Fair Value Measurements

 

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

 

Level 3—Unobservable inputs based on the Company’s assumptions.

 

The Company is required to use observable market data if available without undue cost and effort.

 

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

 

 

Loss per Share

 

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the nine months ended March 31, 2022 and 2021, as there are no potential shares outstanding that would have a dilutive effect.

 

Income Taxes

 

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of March 31, 2022 and June 30, 2021.

 

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

 

Recent Accounting Pronouncements

 

See Footnote 2 of the financial statements for a discussion of recently issued accounting standards.

 

Contractual Obligations and Off-Balance Sheet Arrangements

 

We do not have any contractual obligations or off-balance sheet arrangements.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our Chief Executive Officer as of the end of the period covered by this report, our Chief Executive Officer concluded that our disclosure controls and procedures were not effective as a result of a weakness in the design of internal control over financial reporting identified below.

 

As used herein, “disclosure controls and procedures” mean controls and other procedures of our company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Controls

 

There have been no changes in our internal controls over financial reporting during the period ended March 31, 2022 that have materially affected or are reasonably likely to materially affect our internal controls.

 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not a party to or otherwise involved in any legal proceedings.

 

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

 

Item 1A. Risk Factors.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Not applicable.

 

Item 3. Defaults Upon Senior Securities.

 

There have been no events which are required to be reported under this Item.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits and Financial Statement Schedules

 

31.1

Certification of CEO and CFO. Filed herewith.

32.1

Certification pursuant to 18 U.S.C. Section 1350 of CEO and CFO. Filed herewith.

101.INS*

Inline XBRL Instance Document

 

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Definition

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

AMERICA GREAT HEALTH

   

Dated: May 20, 2022

By: /s/ Quinn Chen                                       

   

Quinn Chen

 
   

Chief Financial Officer

 

 

 

 

 

26
NONE false --06-30 Q3 2022 0001098009 0001098009 2021-07-01 2022-03-31 0001098009 2022-03-31 0001098009 2021-06-30 0001098009 2022-01-01 2022-03-31 0001098009 2021-01-01 2021-03-31 0001098009 2020-07-01 2021-03-31 0001098009 us-gaap:CommonStockMember 2020-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001098009 us-gaap:RetainedEarningsMember 2020-06-30 0001098009 2020-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001098009 2020-07-01 2020-09-30 0001098009 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001098009 us-gaap:CommonStockMember 2020-09-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001098009 us-gaap:RetainedEarningsMember 2020-09-30 0001098009 2020-09-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001098009 2020-10-01 2020-12-31 0001098009 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001098009 us-gaap:CommonStockMember 2020-12-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001098009 us-gaap:RetainedEarningsMember 2020-12-31 0001098009 2020-12-31 0001098009 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001098009 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001098009 us-gaap:CommonStockMember 2021-03-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001098009 us-gaap:RetainedEarningsMember 2021-03-31 0001098009 2021-03-31 0001098009 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001098009 2021-04-01 2021-06-30 0001098009 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001098009 us-gaap:CommonStockMember 2021-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001098009 us-gaap:RetainedEarningsMember 2021-06-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001098009 2021-07-01 2021-09-30 0001098009 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001098009 us-gaap:CommonStockMember 2021-09-30 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001098009 us-gaap:RetainedEarningsMember 2021-09-30 0001098009 2021-09-30 0001098009 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001098009 2021-10-01 2021-12-31 0001098009 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001098009 us-gaap:CommonStockMember 2021-12-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001098009 us-gaap:RetainedEarningsMember 2021-12-31 0001098009 2021-12-31 0001098009 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001098009 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001098009 us-gaap:CommonStockMember 2022-03-31 0001098009 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001098009 us-gaap:RetainedEarningsMember 2022-03-31 0001098009 2017-01-19 2017-01-19 0001098009 aagh:PurecellGroupMember 2020-06-30 0001098009 2021-04-06 2021-04-06 0001098009 us-gaap:CorporateJointVentureMember 2020-12-07 2020-12-07 0001098009 us-gaap:CorporateJointVentureMember 2020-12-07 0001098009 aagh:BrilliantHealthcareLimitedMember us-gaap:CorporateJointVentureMember 2020-12-07 0001098009 us-gaap:CommonStockMember us-gaap:CoVenturerMember 2020-12-07 2020-12-07 0001098009 us-gaap:CashDistributionMember us-gaap:CoVenturerMember 2020-12-07 2020-12-07 0001098009 2021-07-09 2021-07-09 0001098009 us-gaap:CoVenturerMember 2021-07-01 2021-07-31 0001098009 2021-09-03 0001098009 2021-09-03 2021-09-03 0001098009 2021-11-04 0001098009 2021-11-11 2021-11-11 0001098009 2021-11-11 0001098009 2021-11-15 0001098009 aagh:GofBiotechnologiesIncMember 2021-11-15 0001098009 aagh:InternationalInstituteOfGreatHealthIncIIGHMember 2021-02-04 0001098009 us-gaap:MajorityShareholderMember 2021-07-01 2022-03-31 0001098009 us-gaap:MajorityShareholderMember 2022-03-31 0001098009 us-gaap:MajorityShareholderMember 2021-06-30 0001098009 us-gaap:MajorityShareholderMember 2020-07-01 2021-03-31 0001098009 2022-04-12 2022-04-12 0001098009 aagh:Loan1Member 2021-05-05 2021-05-05 0001098009 aagh:Loan1Member 2021-05-05 0001098009 aagh:Loan2Member 2021-06-18 2021-06-18 0001098009 aagh:Loan2Member 2021-06-18 0001098009 aagh:Loan3Member 2021-05-31 0001098009 aagh:Loan3Member 2021-05-31 2021-05-31 0001098009 aagh:Loan3Member 2021-06-03 2021-06-03 0001098009 aagh:Loan4Member 2021-06-18 2021-06-18 0001098009 aagh:Loan4Member 2021-06-23 2021-06-23 0001098009 aagh:Loan4Member 2021-10-28 2021-10-28 0001098009 aagh:Loan3Member 2021-06-18 2021-06-18 0001098009 aagh:Loan3Member 2021-06-18 0001098009 aagh:Loan6Member 2021-10-01 2021-10-01 0001098009 aagh:Loan6Member 2021-10-01 0001098009 aagh:Loan7Member 2021-10-28 2021-10-28 0001098009 aagh:Loan7Member 2021-10-28 0001098009 aagh:Loan8Member 2021-11-01 2021-11-30 0001098009 aagh:Loan8Member 2021-11-30 0001098009 aagh:Loan9Member 2021-11-30 0001098009 aagh:Loan9Member 2021-11-01 2021-11-30 0001098009 aagh:Loan6Member 2021-10-01 2021-10-31 0001098009 aagh:Loan8Member 2021-10-28 2021-10-28 0001098009 aagh:Loan7Member 2021-11-01 2021-11-30 0001098009 aagh:Loan10Member 2021-11-30 0001098009 aagh:LoanReceivedOnApril272021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnApril272021Member 2022-03-31 0001098009 aagh:LoanReceivedOnJune32021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnJune32021Member 2022-03-31 0001098009 aagh:LoanReceivedOnJune42021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnJune42021Member 2022-03-31 0001098009 aagh:LoanReceivedOnJune232021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnJune232021Member 2022-03-31 0001098009 aagh:LoanReceivedOnJuly122021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnJuly122021Member 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember12021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember12021Member 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember222021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember222021Member 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember272021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember272021Member 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember302021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnSeptember302021Member 2022-03-31 0001098009 aagh:LoanReceivedOnOctober292021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnOctober292021Member 2022-03-31 0001098009 aagh:LoanReceivedOnNovember92021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnNovember92021Member 2022-03-31 0001098009 aagh:LoanReceivedOnNovember162021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnNovember162021Member 2022-03-31 0001098009 aagh:LoanReceivedOnNovember182021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnNovember182021Member 2022-03-31 0001098009 aagh:LoanReceivedOnNovember292021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnNovember292021Member 2022-03-31 0001098009 aagh:LoanReceivedOnNovember302021Member 2021-07-01 2022-03-31 0001098009 aagh:LoanReceivedOnNovember302021Member 2022-03-31 0001098009 us-gaap:SeriesAPreferredStockMember 2016-06-30 0001098009 us-gaap:SeriesAPreferredStockMember 2015-07-01 2016-06-30 0001098009 us-gaap:SeriesAPreferredStockMember 2016-08-31 0001098009 aagh:ImediplusIncMember 2021-04-06 2021-04-06 0001098009 aagh:ImediplusIncMember 2021-04-06 0001098009 aagh:PurecellGroupMember 2020-06-30 2020-06-30 0001098009 aagh:PurecellGroupMember 2021-04-06 2021-04-06 0001098009 aagh:PurecellGroupMember 2021-04-06 0001098009 aagh:PurecellGroupMember aagh:AussieProducePTYLTDMember 2021-05-11 2021-05-11 0001098009 aagh:PurecellGroupMember aagh:AussieProducePTYLTDMember 2021-05-11 0001098009 aagh:PurecellGroupMember 2021-05-11 2021-05-11 0001098009 aagh:PurecellGroupMember 2021-05-11 0001098009 2022-03-30 2022-03-30 0001098009 2022-03-30 0001098009 2021-01-21 2021-01-21 0001098009 2021-01-21 0001098009 2021-03-10 2021-03-10 0001098009 2021-03-10 0001098009 2021-04-06 0001098009 2021-04-07 2021-04-07 0001098009 2021-04-07 0001098009 2021-05-05 2021-05-05 0001098009 2021-05-05 0001098009 2021-05-18 2021-05-18 0001098009 2021-05-18 0001098009 aagh:DrTsaiMember 2021-05-18 2021-05-18 0001098009 aagh:DrTsaiMember 2021-05-26 2021-05-26 0001098009 aagh:DrTsaiMember 2021-05-26 0001098009 2021-05-26 2021-05-26 0001098009 2021-05-26 0001098009 2021-06-18 2021-06-18 0001098009 2021-06-18 0001098009 2022-02-02 2022-02-02 0001098009 2022-02-02 0001098009 aagh:Loan4Member 2021-05-31 0001098009 aagh:Loan4Member 2021-06-03 2021-06-03 0001098009 aagh:Loan5Member 2021-10-01 2021-10-31 0001098009 aagh:Loan5Member 2021-10-31 0001098009 aagh:Loan5Member 2021-10-31 2021-10-31 0001098009 aagh:Loan6Member 2021-10-31 2021-10-31 0001098009 aagh:Loan6Member 2021-10-31 0001098009 aagh:Loan6Member 2021-10-28 0001098009 aagh:Loan6Member 2021-10-28 2021-10-28 0001098009 aagh:Loan7Member 2021-11-30 0001098009 aagh:Loan8Member 2022-02-02 2022-02-02 0001098009 aagh:Loan8Member 2022-02-02 0001098009 aagh:Loan4Member 2021-05-31 2021-05-31 0001098009 aagh:PurecellGroupMember 2021-02-10 2021-02-10 0001098009 aagh:PurecellGroupMember 2021-02-10 0001098009 aagh:PurecellGroupMember aagh:AussieProducePTYLTDMember 2021-05-26 2021-05-26 0001098009 aagh:PurecellGroupMember aagh:AussieProducePTYLTDMember 2021-05-26 0001098009 us-gaap:CorporateJointVentureMember 2021-07-01 2022-03-31 0001098009 us-gaap:CorporateJointVentureMember 2022-03-31 0001098009 us-gaap:CorporateJointVentureMember 2018-03-04 0001098009 us-gaap:CorporateJointVentureMember 2018-03-05 2021-12-31 0001098009 us-gaap:ForeignCountryMember 2022-03-31 0001098009 pf0:MinimumMember 2021-07-01 2022-03-31 0001098009 us-gaap:SubsequentEventMember 2022-04-12 2022-04-12 0001098009 aagh:StockPaymentExchangeAgreement1Member 2022-01-28 2022-01-28 0001098009 aagh:StockPaymentExchangeAgreement2Member 2022-01-28 2022-01-28 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings